Plaintiff
4 cases as plaintiff.
Genevant Sciences GmbH is a Swiss-incorporated nucleic acid delivery company headquartered at Viaduktstrasse 8, Basel, Switzerland, with affiliated offices in Cambridge, Massachusetts and Vancouver/Burnaby, British Columbia. It was launched in April 2018 as a jointly owned venture between Roivant Sciences and Arbutus Biopharma. Genevant Sciences GmbH is an indirect subsidiary of Genevant Sciences Ltd.; as of mid-2026 Roivant Sciences Ltd. (Nasdaq: ROIV) held roughly 83% and Arbutus Biopharma (Nasdaq: ABUS) about 16% of Genevant Sciences Ltd. Headcount and standalone revenue figures are not disclosed in public sources.
Genevant is an operating technology company, not a shell. Its business is lipid nanoparticle (LNP) and ligand-conjugate (GalNAc) delivery technology for RNA-based medicines — mRNA, RNAi and gene-editing payloads. Under an April 2018 cross-license with Arbutus, it holds an exclusive, sublicensable worldwide license to Arbutus's LNP and GalNAc patent estate for all fields other than hepatitis B virus and certain exclusions, and it sublicenses that technology to partners and pursues its own RNA programs. Arbutus's LNP platform (125+ international patent families) is used in Alnylam's Onpattro (patisiran).
Genevant is an active two-way litigant, consistent with its case data (4 as plaintiff, 10 as defendant). It is the co-plaintiff with Arbutus in LNP enforcement suits against COVID-19 vaccine makers, and a defendant in Acuitas Therapeutics' 2022 patent suits (S.D.N.Y., D.N.J.) concerning LNP technology. Its affirmative cases have been filed in the District of Delaware and the District of New Jersey rather than the Eastern District of Texas.
Most prominent: Arbutus/Genevant v. Moderna (D. Del., filed Feb. 2022), resolved in March 2026 by a global settlement of up to $2.25 billion ($950 million upfront plus a contingent $1.3 billion), with Moderna consenting to judgments of infringement and no invalidity on four patents. Arbutus/Genevant v. Pfizer and BioNTech (D.N.J., filed April 2023) remains pending, with related Canadian and Unified Patent Court actions added in 2026.
Watchlist
Email-only, free, anonymous. We'll notify you when Genevant Sciences GmbH files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Arbutus and Genevant sued Pfizer and BioNTech in D.N.J. over Comirnaty, asserting 11141378 plus 9504651, 8492359, 11298320, and 11318098. The case remains pending with claim construction on September 9, 2025, and ongoing discovery as of April 26, 2026.
Arbutus and Genevant asserted five LNP patents, including the '359 patent, against Pfizer and BioNTech over Comirnaty. The action remains pending after a September 2025 claim construction ruling and was carved out of the Moderna settlement.
Arbutus and Genevant sued Moderna over the Moderna COVID-19 vaccine, originally asserting six patents including US 8,822,668. The '668 patent was dropped during bilateral narrowing before trial. The case settled globally on March 3, 2026, with Moderna consenting to judgment on the four surviving patents, and Moderna later appealed.
Arbutus and Genevant sued Moderna and ModernaTX in D. Del. asserting six LNP patents, including 11141378. The case settled March 3, 2026 as part of a $2.25 billion global settlement; Moderna consented to a judgment of infringement and no invalidity on four asserted patents, and the docket terminated March 4, 2026.